Submit Your Article CMED MEACR meeting
Home Print this page Email this page Users Online: 468
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 10  |  Issue : 6  |  Page : 294-299

Sarcopenia is a predictive marker for response to erlotinib in patients with lung adenocancer


1 Department of Medical Oncology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
2 Department of Medical Oncology, Kahramanmaras Sutcu Imam University Faculty of Medicine, Kahramanmaras, Turkey
3 Department of Nuclear Medicine, Gaziantep University Faculty of Medicine, Gaziantep, Turkey

Correspondence Address:
Havva Yesil Cinkir
Department of Medical Oncology, Gaziantep University Faculty of Medicine, Gaziantep 27310
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ccij.ccij_185_20

Rights and Permissions

Background: Adenocancer pathologic subtype, smoking history, and women gender have been known to predict the parameters such as the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer (NSCLC); however, we need new predictive markers as well as driver mutations for better treatment options. The aim of this study is to investigate the predictive role of sarcopenia in lung adenocancer patients treated with erlotinib. Materials and Methods: This study was designed as retrospectively. Skeletal muscle index (SMI) was measured with a single cross-sectional area of the muscle at the third lumber vertebra (L3, cm2)/(height × height)(m2). Sarcopenia was defined by median cutoff values of SMI of women (<28.2 cm2/m2) and men (<32.7 cm2/m2). The predictive role of sarcopenia and other parameters was assessed by the cox-regression model. Results: The median age was 56 years (range, 36–84). Median progression-free survival (PFS) was 38 (95% confidence interval [CI]: 21.3–54.6) weeks in the sarcopenic group and 49 (95% CI: 0–101.4) weeks in the nonsarcopenic group (P = 0.053). In multivariate analysis, the presence of sarcopenia and number of metastatis were the independent predictive factors for PFS. Disease control rate and overall survival were not significantly different between sarcopenic and nonsarcopenic groups. Conclusion: We found that the presence of sarcopenia and number of metastasis were a predictive marker in NSCLC patients treated with erlotinib. It is important to recognize sarcopenia early and manage patients accordingly.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed368    
    Printed12    
    Emailed0    
    PDF Downloaded55    
    Comments [Add]    

Recommend this journal